Subclinical Hypothyroidism: Should You Treat It?

Your TSH is slightly elevated but your T4 is normal. Is treatment necessary? The answer depends on factors most doctors never consider.

Subclinical hypothyroidism is one of the most debated topics in endocrinology. By definition, it means your TSH is elevated while your free T4 remains in the normal range. Conventional medicine often takes a watch and wait approach. But is that really the best strategy?

Let me share what the latest evidence tells us, and what I see in clinical practice.

First, the numbers matter. A TSH of 5.5 is very different from a TSH of 9.0, even though both technically fall into the subclinical category. Research consistently shows that higher TSH levels, particularly above 7.0, are associated with increased cardiovascular risk and progression to overt hypothyroidism.

Second, symptoms matter. Many patients with subclinical hypothyroidism have real symptoms including fatigue, weight gain, brain fog, and depression. The fact that their T4 is still normal does not mean their cells are receiving adequate thyroid hormone.

Third, antibodies matter enormously. If you have subclinical hypothyroidism plus positive thyroid antibodies, your risk of progression to overt hypothyroidism is substantially higher. Early treatment in this group may slow autoimmune progression.

The 2024 European Thyroid Association guidelines now recommend considering treatment for symptomatic patients with TSH above 7.0 or for those with positive antibodies. This represents a shift toward earlier intervention.

My approach is individualized. I consider the whole picture: TSH level, symptoms, antibody status, cardiovascular risk factors, and patient preference. Sometimes treatment makes a dramatic difference. Sometimes watchful waiting is appropriate. But waiting should never mean ignoring.

You deserve a physician who takes your symptoms seriously, regardless of where your labs fall on a reference range.